These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31088543)

  • 1. One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy.
    Weng HY; Huang TL; Chang PY; Wang JK
    BMC Pharmacol Toxicol; 2019 May; 20(1):29. PubMed ID: 31088543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Komuku Y; Iwahashi C; Gomi F
    Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy.
    Ito A; Maruyama-Inoue M; Kitajima Y; Sato S; Inoue T; Yamane S; Kadonosono K
    PLoS One; 2020; 15(6):e0235213. PubMed ID: 32579608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Nakai S; Matsumiya W; Keiko O; Miki A; Nakamura M; Honda S
    Jpn J Ophthalmol; 2019 Jan; 63(1):100-108. PubMed ID: 30406511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Intravitreal Aflibercept Treat and Extend for Polypoidal Choroidal Vasculopathy in the ATLANTIC Study: A Randomized Clinical Trial.
    Silva R; Arias L; Nunes S; Farinha C; Coimbra R; Marques JP; Cachulo ML; Figueira J; Barreto P; Madeira MH; Pires I; Sousa JC; Distefano L; Rosa P; Carneiro Â; Vaz-Pereira S; Meireles A; Cabrera F; Bures A; Mendonça L; Fernandez-Vega-Sanz A; Barrão S; Koh A; Cheung CMG; Cunha-Vaz JG; Murta J;
    Ophthalmologica; 2022; 245(1):80-90. PubMed ID: 34348351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvements of Retinal Sensitivity after Intravitreal Injection of Aflibercept in Eyes with Neovascular Age-Related Macular Degeneration with or without Polypoidal Choroidal Vasculopathy.
    Nizawa T; Kitahashi M; Baba T; Iwase T; Kubota-Taniai M; Hattori Y; Shiko Y; Kawasaki Y; Iwase T; Sato T; Ogawa S; Sugawara T; Yamamoto S
    Ophthalmologica; 2021; 244(4):347-360. PubMed ID: 34015785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
    Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
    Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy.
    Vyas CH; Cheung CMG; Tan C; Chee C; Wong K; Jordan-Yu JMN; Wong TY; Tan A; Fenner B; Sim S; Teo KYC
    BMJ Open; 2021 Jul; 11(7):e050252. PubMed ID: 34266844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
    Yamamoto A; Okada AA; Kano M; Koizumi H; Saito M; Maruko I; Sekiryu T; Iida T
    Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol for a randomised, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC study.
    Marques JP; Farinha C; Costa MÂ; Ferrão Â; Nunes S; Silva R
    BMJ Open; 2017 Aug; 7(8):e015785. PubMed ID: 28851779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.
    Lee WK; Iida T; Ogura Y; Chen SJ; Wong TY; Mitchell P; Cheung GCM; Zhang Z; Leal S; Ishibashi T;
    JAMA Ophthalmol; 2018 Jul; 136(7):786-793. PubMed ID: 29801063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
    Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.
    Ngo WK; Chee WK; Tan CS; Lim TH
    BMC Ophthalmol; 2020 Apr; 20(1):150. PubMed ID: 32293353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions.
    Matsumoto H; Mukai R; Kikuchi Y; Morimoto M; Akiyama H
    Jpn J Ophthalmol; 2020 Mar; 64(2):203-209. PubMed ID: 32016666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for combined ranibizumab and prompt verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
    Hsia Y; Chan LW; Yang CH; Yang CM; Hsieh YT
    Photodiagnosis Photodyn Ther; 2019 Sep; 27():227-233. PubMed ID: 31195145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy.
    Kikushima W; Sakurada Y; Sugiyama A; Tanabe N; Kume A; Iijima H
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):311-316. PubMed ID: 27534663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
    Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
    BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy.
    Sato T; Kishi S; Matsumoto H; Mukai R
    Am J Ophthalmol; 2010 Jun; 149(6):947-954.e1. PubMed ID: 20346441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
    Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
    Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.